TuesdayJan 31, 2017 3:52 pm

eXp World Holdings, Inc. (EXPI) Using Virtual Reality to Better Train its Agents and Brokers

Brokers have been using virtual reality for a long time, but augmented reality, or AR, is expected to be a new trend for 2017, according to the ‘Emerging Trends in Real Estate 2017’ report published by PWC (http://nnw.fm/PZ7Gy). With the emergence of Pokémon Go, it became clear that augmented reality could prompt over 10 million people to leave their homes and search for digital characters. Could it somehow do the same for the real estate industry? Despite basic AR technology having been around for some time, brokers are now using it to show tenants and potential buyers customizable experiences not…

Continue Reading

TuesdayJan 31, 2017 2:34 pm

Moxian, Inc. (NASDAQ: MOXC) Expanding Into Shanghai, Guangzhou In 2017

Moxian, Inc. (NASDAQ: MOXC) is expanding into Shanghai and Guangzhou in 2017 from its existing direct sales offices in Beijing and Shenzhen. It is targeting further growth in the expanding online-to-offline (O2O) market in China from merchant paid subscriptions and the increase in online sales, predominantly from women. The January 10, 2017, Crystal Equity Research Report (http://nnw.fm/NupY5) on Moxian projects that the company will generate revenues of $2.3 million by fiscal year end 2018. Moxian has its own online mobile platform in China’s growing O2O market, Moxian+. It offers both a consumer app, Moxian+ User, and a business app, Moxian+…

Continue Reading

TuesdayJan 31, 2017 2:00 pm

Arch Therapeutics, Inc. (ARTH) Starts Presentation at NobleCon13

Arch Therapeutics (OTC: ARTH) operates as a life science medical device company. Arch develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. The company’s primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. For more information, visit the company’s website at www.archtherapeutics.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution…

Continue Reading

TuesdayJan 31, 2017 2:00 pm

Cellectar Biosciences, Inc. (NASDAQ: CLRB) Starts Presentation at NobleCon13

Cellectar Biosciences (NASDAQ: CLRB) is engaged in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. It offers CLR 131, a PDC radiotherapeutic product candidate currently being evaluated in a phase I study for the treatment of relapse or refractory multiple myeloma; CLR 125, a cancer-targeting radiotherapeutic is under pre-clinical investigation for the treatment of micrometastatic disease ; CLR 124, a cancer-targeting positron emission tomography (PET) imaging PDC for the selective detection of tumors and metastases in a broad range of cancers; and CLR 1502, a cancer-targeting NIR-fluorophore optical imaging PDC for intraoperative tumor…

Continue Reading

TuesdayJan 31, 2017 1:39 pm

Palatin Technologies, Inc. (PTN) Takes Bremelanotide to Phase 3 Clinical Trials for Hypoactive Sexual Desire Disorder (HSDD)

Hypoactive Sexual Desire Disorder, or HSDD, is a common female sexual dysfunction where the woman feels a decrease in sexual desire and an increase in personal distress from this lack of desire. It’s a disorder affecting approximately one in 10 women, and it often leads to relationship issues. According to 'Hypoactive Sexual Desire Disorder: A Review of Epidemiology, Biopsychology, Diagnosis, and Treatment' (http://nnw.fm/Auo7u), HSDD is present in just under 9% of women aged 18 to 44, over 12% of women aged 45 to 64, and over 7% of women aged over 65. The report continues to explain that more than…

Continue Reading

TuesdayJan 31, 2017 1:30 pm

BioTime, Inc. (NYSE: BTX) Starts Presentation at NobleCon13

BioTime (NYSE: BTX)  is engaged in developing and commercializing novel therapies based on HyStem cell delivery and pluripotent stem cell technology platforms. The company focuses on regenerative medicine and is developing Renevia, currently in pivotal clinical trial for HIV related facial lipoatrophy; AST-VAC1, a cancer immunotherapy in phase II clinical trials for the treatment of acute myeloid leukemia; OpRegen, in phase I/IIa clinical trial to treat the dry form of age-related macular degeneration; and AST-OPC1, in phase I/II clinical trials for spinal cord injuries. The company also develops Premvia for wound management. For more information, visit the company’s website at www.biotimeinc.com.…

Continue Reading

TuesdayJan 31, 2017 1:30 pm

Comtech Telecommunications Corp. (NASDAQ: CMTL) Starts Presentation at NobleCon13

Comtech Telecommunications (NASDAQ: CMTL) designs, develops, produces and markets products, systems and services for communications solutions. The company’s Commercial Solutions segment provides ground-based equipment; traveling wave tube amplifiers comprising high power narrow-band amplifiers that are used to amplify signals from satellite earth stations; and safety and security technology solutions that enable 911 call routing. This segment also offers enterprise application technologies, including location-based technology, such as Trusted Location, a software-based scoring system that allows providers to determine mobile location and identify fraudulent behavior and other security risks; and Look4, an application that enables customers to build their own applications. For…

Continue Reading

TuesdayJan 31, 2017 1:30 pm

Aytu BioScience, Inc. (AYTU) Starts Presentation at NobleCon13

Aytu BioScience (OTC: AYTU) is a specialty healthcare company that focuses on developing and commercializing novel products in the field of urology in the United States. The company markets Natesto for the treatment of hypogonadism (low testosterone) in men; ProstaScint for use in newly diagnosed high-risk prostate cancer patients and patients with recurrent prostate cancer; and Primsol, an oral solution for urinary tract infections. It is also involved in commercializing of the RedoxSYS System for research use in various applications. In addition, the company is developing MiOXSYS, an in vitro diagnostic semen analysis test that is used in the quantitative…

Continue Reading

TuesdayJan 31, 2017 1:00 pm

Torchlight Energy Resources, Inc. (NASDAQ: TRCH) Starts Presentation at NobleCon13

Torchlight Energy (NASDAQ: TRCH) engages in the acquisition, exploration, exploitation, and/or development of oil and natural gas properties in the United States. It has interests in four oil and gas projects, including the Marcelina Creek Field Development in Wilson County, Texas; the Ring Energy Joint Venture in Southwest Kansas; the Hunton play in Central Oklahoma; and the Orogrande project in Hudspeth County, Texas. It also had interest in a commercial salt water disposal facility in Seminole, Oklahoma. For more information, visit the company’s website torchlightenergy.com About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a…

Continue Reading

TuesdayJan 31, 2017 1:00 pm

NovoCure Ltd. (NASDAQ: NVCR) Starts Presentation at NobleCon13

NovoCure (NASDAQ: NVCR) is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields (TTFields) for the treatment of solid tumor cancers. The company’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.  Headquartered in Jersey, Novocure has operations in Portsmouth, New Hampshire; Malvern, Pennsylvania; and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel.  For more information, visit the company’s…

Continue Reading

Contact us: 212.418.1217